ghk-cu clinical studies dosage human 7% ACCELERANT GHK-Cu Peptide Therapy: The Definitive
Description
P-15 enhances cell attachment to bone substitutes and upregulates extracellular matrix (ECM) production [112]
The SURMOUNT-1 trial (N=2,539) showed tirzepatide 15 mg produced 20.9% mean body-weight reduction at 72 weeks [12]
Based on these studies it seems that the nitrogen retaining properties of GH predominantly involve stimulation of protein synthesis without affecting (lowering) proteolysis
Fully customized formulas, custom molds, special packaging, or advanced testing may need longer development time
